CSF1R and undifferentiated pleomorphic sarcoma: However, TAM depletion with pan-macrophage depleting antibodies used as monotherapy (e.g., anti-CSF1R antibodies) has shown limited efficacy both in humans and mice [48], including a mouse model of undifferentiated pleomorphic sarcoma [51], thus calling for a better understanding of TAM phenotypes and interactions with other components of the TME for the identification of more efficient strategies.